NASDAQ — Healthcare: Manufacturing, Diagnostics & Research: Pharmaceutical Preparations
www.aclaristx.comThe MK2 Inhibitor in Combination With mFOLFIRINOX clinical trial, sponsored by Washington University School of Medicine, is expected to be completed by May 31, 2030. This Phase 1 trial aims to evaluate the efficacy of MK2 inhibition in enhancing the effectiveness of mFOLFIRINOX chemotherapy for patients with untreated metastatic pancreatic ductal adenocarcinoma (PDAC). Currently, the trial is in the recruiting stage with an enrollment target of 51 participants. The trial information can be found at the provided link.
Clinical Trial CompletionThe clinical trial evaluating zunsemetinib, in combination with capecitabine for patients with hormone receptor-positive and HER2-negative metastatic breast cancer, is expected to complete on May 31, 2032. The Phase Ib/II study, sponsored by Washington University School of Medicine, aims to assess the safety and efficacy of this combination treatment. The trial is currently recruiting 152 participants and reflects ongoing research into potential therapies for this subtype of breast cancer.
Clinical Trial Completion DatePatent US10098910 for ESKATA, a product by Aclaris Therapeutics Inc, is set to expire on April 21, 2035. ESKATA is a stabilized hydrogen peroxide formulation used for treating various skin conditions, including warts and seborrheic keratosis. The expiration may impact the competitive landscape as generic versions of the drug could enter the market, potentially affecting Aclaris' market share and revenue.
Patent ExpirationThe patent US9675639 for ESKATA, a product from Aclaris Therapeutics Inc used in treating skin conditions, including warts and seborrheic keratosis, will expire on July 4, 2035. The patent covers a stable formulation that includes hydrogen peroxide and 2-propanol, along with applicators for dispensing. The expiry of this patent could allow for increased competition in the market, potentially affecting Aclaris Therapeutics' financial performance as generic alternatives may enter the market.
Patent Expiry